Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study

Article information

Diabetes Metab J. 2020;44(1):67-77
Publication date (electronic) : 2019 July 11
doi : https://doi.org/10.4093/dmj.2018.0274
1Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
3Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
4Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
5Department of Internal Medicine, Busan St. Mary's Hospital, Catholic University of Pusan, Busan, Korea.
6Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
7Department of Internal Medicine, Daedong Hospital, Busan, Korea.
8Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
9Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea.
Corresponding author: In Joo Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea. injkim@pusan.ac.kr
*Jeong Mi Kim and Sang Soo Kim contributed equally to this study as first authors.†Current affiliation: Department of Internal Medicine, Isam Hospital, Busan, Korea
Received 2018 December 21; Accepted 2019 February 17.



There is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. This study assessed the efficacy and safety of pioglitazone or glimepiride when added to metformin plus alogliptin treatment for T2DM.


This multicenter, randomized, active-controlled trial (ClinicalTrials.gov: NCT02426294) recruited 135 Korean patients with T2DM that was inadequately controlled using metformin plus alogliptin. The patients were then randomized to also receive pioglitazone (15 mg/day) or glimepiride (2 mg/day) for a 26-week period, with dose titration was permitted based on the investigator's judgement.


Glycosylated hemoglobin levels exhibited similar significant decreases in both groups during the treatment period (pioglitazone: −0.81%, P<0.001; glimepiride: −1.05%, P<0.001). However, the pioglitazone-treated group exhibited significantly higher high density lipoprotein cholesterol levels (P<0.001) and significantly lower homeostatic model assessment of insulin resistance values (P<0.001). Relative to pioglitazone, adding glimepiride to metformin plus alogliptin markedly increased the risk of hypoglycemia (pioglitazone: 1/69 cases [1.45%], glimepiride: 14/66 cases [21.21%]; P<0.001).


Among patients with T2DM inadequately controlled using metformin plus alogliptin, the addition of pioglitazone provided comparable glycemic control and various benefits (improvements in lipid profiles, insulin resistance, and hypoglycemia risk) relative to the addition of glimepiride.


When medical treatment is necessary for type 2 diabetes mellitus (T2DM), physicians and patients prefer oral antidiabetic drugs [1]. However, it can be difficult to achieve and maintain glycemic control using a single antidiabetic agent. Thus, to achieve glycemic goals and reduce the risk of chronic diabetic complications, combinations of antidiabetic drugs are required for most patients [234]. Nevertheless, the combination therapy must be carefully selected to achieve an additive effect on glycemic control, and this approach is guided by the drugs' mechanisms of action and side effects [5]. Furthermore, social factors and insurance coverage can strongly influence the drugs that are selected for combination therapy [6].

Metformin is widely used as the initial antidiabetic agent [23], and dipeptidyl peptidase-4 (DPP-4) inhibitors are becoming increasingly common as a second agent that is combined with metformin [789]. For example, the number of American patients receiving metformin plus DPP-4 inhibitors has increased sharply [7]. This combination therapy is also prescribed for the overwhelming majority of Korean patients with T2DM [89]. Unfortunately, many patients cannot achieve or maintain their glycemic goals using only metformin plus DPP-4 inhibitors [10], and it can be difficult to select an appropriate third-line therapy for these patients. In Korea, the current health insurance system covers sulfonylurea (SU) or thiazolidinedione (TZD) as common third-line agents [11].

In East Asia, β-cell dysfunction has traditionally been recognized as the main etiological factor for T2DM [12]. However, recent evidence supports the importance of insulin resistance as the main pathogenic mechanism for T2DM in Korea [1314]. Therefore, it would be useful to compare the efficacies of SU or TZD when combined with metformin plus DPP-4 inhibitors in the third-line setting. The present study evaluated the efficacy and safety of adding pioglitazone or glimepiride for patients with T2DM that was inadequately controlled using metformin plus alogliptin.


Study design

This multicenter, randomized, open-label, parallel design, phase IV trial (ClinicalTrials.gov: NCT02426294) was conducted between March 2015 and April 2018 at eight Korean centers. The study consisted of a 2-week screening period, a 26-week treatment period, and a 4-week follow-up period. The study protocol and other related documents were reviewed and approved by the Institutional Review Board (IRB No.: 1412-001-037) at each center. All patients provided written informed consent before their enrolment. The study complied with the Declaration of Helsinki, the Guidelines for Good Clinical Practice, and the applicable local laws and regulations.

Patients and eligibility

Patients with inadequately controlled T2DM (glycosylated hemoglobin [HbA1c] of 7.5% to <10%) were considered eligible if they had consistently received metformin plus alogliptin for ≥3 months before randomization, were 19 to 80 years old, and had a body mass index (BMI) of 18.5 to 35 kg/m2. The key exclusion criteria were type 1 diabetes mellitus, heart failure or history of heart failure (New York Heart Association Class III or IV), major cardiovascular disorders (e.g., myocardial infarction, cardiovascular intervention, stroke, and transient ischemic attack) during the last 6 months, renal or hepatic dysfunction (creatinine clearance <50 mL/min or elevated levels of aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, or total bilirubin to ≥2.5×the upper normal limit), and pregnancy, breastfeeding, or unwillingness to use appropriate contraceptive measures (for women of reproductive age).

Data collection

The baseline and follow-up examinations included a physical examination, laboratory testing, medical review, and an in-person interview to collect information regarding medical conditions. Self-reported historical data (“yes” or “no”) regarding diabetic retinopathy and diabetic neuropathy were collected at the screening. The conventional method was used to calculate BMI (kg/m2). Serum specimens were typically collected after an 8-hour overnight fast and stored at −70℃ after processing.


Participants were randomly assigned to receive either pioglitazone (15 mg/day) or glimepiride (2 mg/day) in addition to their current treatment using metformin plus alogliptin. After 12 weeks of treatment, the doses could be adjusted to 30 mg/day for pioglitazone or 4 mg/day for glimepiride, based on the investigator's decision.

Study outcome

The primary efficacy outcome was defined as the change in HbA1c levels from baseline to the end of treatment using pioglitazone or glimepiride. The secondary efficacy outcomes measures included the 26-week changes in lipid profiles, homeostatic model assessment of insulin resistance (HOMA-IR), and homeostatic model assessment β-cell function (HOMA-β), as well as the 12-week change in HbA1c levels (baseline to 12 weeks).

At each visit, all adverse events (AEs) were recorded and assessed for severity and possible relationship to the study medications. Participants performed self-monitored blood glucose (SMBG) testing at least once per day, or at any time when they experienced hypoglycemic symptoms. A hypoglycemic event was defined as confirmed hypoglycemia based on related symptoms and a SMBG result of <60 mg/dL, or any episode requiring intervention regardless of blood glucose levels. Other AEs were obtained via participant self-reporting.

Statistical analyses

The required sample size (154 patients divided evenly between the two groups) was calculated to achieve 90% power to detect a difference of 0.5% in HbA1c (σΔ2=1.71% and a two-sided α=0.05) between the baseline and 26-week measurements. The assumed drop-out rate was 20%.

Analyses of the primary efficacy outcome and safety were performed based on the intention-to-treat (ITT) population, which was defined as participants who were exposed to at least one dose and then underwent at least one post-baseline assessment, and based on the per-protocol (PP) population, which was defined as participants who completed the study without any major protocol violation. The PP population was also used to analyze secondary efficacy outcomes and to compare efficacy outcomes between the two groups. The independent t-test was used to compare continuous variables between the two groups, while the paired t-test was used to compare the pre- and post-efficacies. The chi-square test or Fishe's exact test were used to compare categorical variables between the groups. All tests were two-tailed, and significance was set at P=0.05. All statistical analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA).


Baseline characteristics

Fig. 1 shows the study flowchart. A total of 161 patients were screened for this study, and 135 patients (the ITT population) were randomized to receive pioglitazone (n=69) or glimepiride (n=66). After randomization, 19 patients dropped out and 116 patients (the PP population) completed the 26-week treatment using pioglitazone (n=58) or glimepiride (n=58). The most common reason for discontinuation was withdrawal of consent (seven patients in each group).

Fig. 1

Study flowchart.

The baseline demographic and clinical characteristics were similar between the two groups in the ITT population (Table 1) and the PP population (data not shown). The mean duration of diabetes was approximately 10 years and the baseline HbA1c level was approximately 8.2%. The drug compliance rates during the study period were 95.5% for pioglitazone and 96.4% for glimepiride. At the 12-week evaluation, the treatment doses were adjusted for 13 patients in the pioglitazone group (to 30 mg/day) and for 17 patients in the glimepiride group (to 1 mg/day for seven patients, 3 mg/day for three patients, and 4 mg/day for seven patients).

Baseline demographic and clinical characteristics (ITT population)

Primary efficacy outcomes

Between baseline and the end of treatment, the HbA1c levels decreased significantly in both groups of the ITT population (P<0.001). The baseline HbA1c levels were 8.25%±0.58% in pioglitazone group and 8.16%±0.61% in glimepiride group. The corresponding changes in the HbA1c levels after 26 weeks were −0.81%±1.1% and −1.05%±0.87%, and no significant inter-group difference was observed (P=0.165) (Table 2).

Primary and secondary outcomes, according to treatment group at 26 weeks

In the PP population, the baseline HbA1c levels were not different between the pioglitazone group (8.21%±0.56%) and the glimepiride group (8.20%±0.63%). Similar to in the ITT population, the HbA1c levels in the PP population had decreased significantly by week 26 (P<0.001), although the inter-group difference was also not significant (pioglitazone: −1.04%±0.94%, glimepiride: −1.12%±0.87%; P=0.630). The proportion of participants achieving HbA1c <7.0% at the end of treatment was 48.3% with glimepiride (28/58) and 44.8% with pioglitazone (26/58) in the PP population (data not shown).

Secondary efficacy outcomes

The decreases in HbA1c levels between baseline and week 12 exhibited similar patterns to the changes between baseline and week 26. However, significant differences were observed between the pioglitazone and glimepiride groups in both the ITT population and the PP population (ITT: −0.64%±0.95% vs. −1.08%±0.73%, P=0.003; PP: −0.86%±0.76% vs. −1.16%±0.70%, P=0.029) (Fig. 2A).

Fig. 2

Changes in the measured variables at 12 weeks and 26 weeks. Mean±standard error values at baseline, 12 weeks, and 26 weeks were calculated for (A) glycosylated hemoglobin (HbA1c), (B) homeostatic model assessment of insulin resistance (HOMA-IR), (C) high density lipoprotein cholesterol (HDL-C), and (D) triglycerides during 26-week treatments using glimepiride (closed triangles) or pioglitazone (closed quadrangles) for patients with type 2 diabetes mellitus who were concurrently receiving combination therapy using alogliptin and metformin. aP<0.05.

The baseline HOMA-IR values were 4.10±3.03 in the pioglitazone group and 3.98±3.01 in the glimepiride group. At week 26, the HOMA-IR values had only decreased significantly in the pioglitazone group (2.58±1.56, P<0.001). However, there was no significant difference in the HOMA-IR changes of the two groups (pioglitazone: −1.53±2.74, glimepiride: −0.54±2.72; P=0.054) (Table 2, Fig. 2B). The absolute HOMA-β values, and the 26-week changes, were not significantly different between the two groups.

In the pioglitazone group of the PP population, the high density lipoprotein cholesterol (HDL-C) levels increased significantly from 49.19±14.20 mg/dL at baseline to 54.76±18.18 mg/dL at week 26 (P<0.001). However, no significant change in the HDL-C levels was observed in the glimepiride group (47.22±9.91 mg/dL at baseline and 48.16±11.29 mg/dL at week 26, P=0.403). There was a significant difference in the magnitude of the change in HDL-C levels when we compared the pioglitazone and glimepiride groups in the PP population (5.57±9.58 mg/dL vs. 0.94±8.47 mg/dL, P=0.007) (Table 2, Fig. 2C).

Triglyceride levels also decreased significantly in both groups (pioglitazone: 132.84±72.15 mg/dL to 113.02±51.47 mg/dL, P=0.034; glimepiride: 146.17±71.58 mg/dL to 130.72±67.03 mg/dL, P=0.043). However, there was no significant inter-group difference in the magnitude of these changes (−19.83±69.69 mg/dL vs. −15.45±56.76 mg/dL, P=0.711) (Table 2, Fig. 2D).


Table 3 shows the safety outcomes for each treatment. A total of 122 patients (90.4%) reported at least one treatment-emergent AE (pioglitazone: 64/69 patients [92.75%], glimepiride: 58/66 patients [87.88%]; P=0.504). The most frequent AEs were upper respiratory tract infection (10/69, 14.49%) in the pioglitazone group and hypoglycemia (16/66, 24.24%) in the glimepiride group. The glimepiride group was more likely than the pioglitazone group to experience AEs that were rated as being possibly/probably/definitely related to the study drug (i.e., adverse drug reactions) (pioglitazone: eight patients [11.59%], glimepiride: 23 patients [34.85%]; P=0.003). The most frequently reported adverse drug reaction was hypoglycemia, which was significantly more common in the glimepiride group (pioglitazone: 1/69 [1.45%], glimepiride: 14/66 [21.21%]; P=0.001). Two patients in the pioglitazone group discontinued the study because of AEs. Two patients in the pioglitazone group reported experiencing trauma-related fractures (serious AEs), with one case involving a femoral fracture after a fall from second-floor stairs and the second case involving a toe fracture after unintentionally kicking a table leg. A third patient in the pioglitazone group experienced acute pyelonephritis as a serious AE. The investigators judged that these three events were not related to the study medication. The other AEs were generally considered mildly to moderately severe.

Adverse events summary


Among patients with inadequately controlled T2DM receiving metformin plus alogliptin, the addition of glimepiride or pioglitazone for 26 weeks significantly improved glycemic control. Relative to glimepiride, pioglitazone provided similar efficacy of glycemic control with fewer episodes of hypoglycemia. Furthermore, pioglitazone improved the patients' lipid profiles and HOMA-IR values. The addition of both drugs to metformin plus alogliptin provided a good safety profile with no previously unknown safety concerns.

The Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) aimed to compare the long-term effects of second-line pioglitazone or SUs, given in addition to metformin monotherapy, on cardiovascular events in patients with T2DM [15]. The results indicate that both SUs and pioglitazone had similar effects, when combined with metformin, on the incidence of total cardiovascular events. However, relative to metformin plus SUs, metformin plus pioglitazone provided better durability of glycemic control and a lower frequency of hypoglycemia. Similarly, our results indicate that adding pioglitazone to metformin plus alogliptin provided similar glycemic control but a lower risk of hypoglycemia compared to adding glimepiride. The TOSCA.IT trial was focused on second-line treatment for T2DM while our study suggests that pioglitazone was suitable alternatives as add-on treatment to metformin plus alogliptin combination treatment.

Various pathophysiological factors contribute to hyperglycemia, which inevitably requires combining antidiabetic agents with different mechanisms of action to successfully manage T2DM [234]. Metformin remains the first-line agent for treating T2DM, although recent recommendations have suggested patient-centered glycemic management, albeit without specific recommendations regarding the optimal second-line and third-line antidiabetic agents. In this context, insulin resistance is a major pathophysiological factor that influences T2DM, and improving insulin sensitivity is extremely important in the management of T2DM [1617]. Although metformin is usually classified as an insulin sensitizer [181920], its efficacy as an insulin sensitizer is very limited, while TZD has been recognized as a true insulin sensitizer [212223]. However, safety concerns were raised regarding the use of rosiglitazone, which has led to TZD being used infrequently [24].

The disadvantages of DPP-4 inhibitors include a modest glucose-lowering effect and an increased risk of hospitalization for heart failure [2526]. However, DPP-4 inhibitors are also associated with a markedly reduced risk of hypoglycemia [27], which has led to DPP-4 inhibitors typically being selected as the second-line agent after metformin monotherapy fails. Furthermore, there is an increasing number of patients who are receiving combination therapy using metformin plus a DPP-4 inhibitor [789], with >50% of Korean patients receiving this combination [9]. However, metformin plus a DPP-4 inhibitor provides unsatisfactory glycemic control, which inevitably leads to the addition of a third-line agent.

Pioglitazone is a well-recognized insulin sensitizer with similar glucose-lowering power to glimepiride, albeit with a slower response [28]. The findings of the present study also validate this point. For example, there was a significant difference between the pioglitazone and glimepiride groups at 12 weeks in terms of their changes in HbA1c levels, although this difference disappeared at the 26-week measurement. A slow-onset but durable glycemic control is a well-established characteristic of TZD treatment, and the rarity of hypoglycemia is another well-known benefit of pioglitazone treatment [29]. As expected, the addition of glimepiride was associated with more hypoglycemic events than after the addition of pioglitazone. Approximately 24% of patients in the glimepiride group experienced hypoglycemia, although severe hypoglycemic events were not observed in both treatment groups.

Pioglitazone improves the function of β-cells and adipose tissue [303132], with elevated production of adipokines (e.g., adiponectin and leptin) stimulating fatty acid uptake that helps protect non-adipose tissue from abnormal lipid accumulation [33]. However, the present study failed to detect significant increases in HOMA-β after the addition of glimepiride or pioglitazone to the patients' treatment. Nevertheless, the onset of diabetes is preceded by impaired insulin secretion, and we noted that most patients had an approximately 10-year history of diabetes, which may explain the lack of improvement in β-cell function. Furthermore, Korean patients with T2DM more commonly exhibit an insulin secretory defect leading to the development of diabetes, relative to Caucasian patients with a similar duration of diabetes [12]. Therefore, we conclude that glimepiride and pioglitazone were both unable to alter the patients' insulin secretory function in this study.

A recent study revealed that pioglitazone was safely used for 18 months in 101 patients with prediabetes or T2DM, as well as biopsy-proven non-alcoholic steatohepatitis, with 51% of the patients experiencing resolution of the non-alcoholic steatohepatitis [34]. In the present study, the pioglitazone group exhibited significant 26-week decreases in the values for HOMA-IR (−1.53±2.74, P<0.001), AST (−2.6±8.4 IU/L, P=0.012), and ALT (−6.4±11.8 IU/L, P<0.001). In addition, the magnitude of the decreases in the liver enzyme levels from baseline were significantly larger in the pioglitazone group than in the glimepiride group (P=0.011 for AST, P=0.01 for ALT). An increase in HDL-C and a decrease in triglyceride levels are well-known effects of pioglitazone treatment [3536], and the present study revealed similar findings. After 26 weeks of treatment, the pioglitazone group exhibited a significant increase in HDL-C, while both groups exhibited similar decreases in triglycerides, and neither group exhibited changes in low density lipoprotein cholesterol levels.

Weight gain and edema are frequently reported during TZD treatment [3738], although the present study revealed minimal incidences of these events, and none of the patients discontinued treatment because of these events. These findings might be explained by the fact that metformin has anorexic properties and is associated with an increase in gastrointestinal side effects [39]. Thus, any TZD-related weight gain might be minimized when it is added to a treatment regimen that includes metformin. An increased risk of fracture is a recently emerged adverse effect of TZD treatment [40], and we identified two fracture cases in the pioglitazone group. The first case involved a femoral fracture after a fall off from second-floor stairs and the second case involved a toe fracture after accidentally kicking a table leg. The investigators judged these fractures to not be related to the study medication, and we conclude that both pioglitazone and glimepiride were well tolerated throughout the study period.

In conclusion, the addition of pioglitazone to metformin plus alogliptin for patients with inadequately controlled T2DM resulted in a similar decrease in HbA1c levels to that induced by the addition of glimepiride. However, in addition to the comparable level of glycemic control, pioglitazone provided several better outcomes (improvements in lipid control, insulin resistance, and hypoglycemia risk). Therefore, pioglitazone can be used effectively and safely as a third-line agent for managing patients whose T2DM is not adequately controlled using metformin plus a DPP-4 inhibitor.




CONFLICTS OF INTEREST: This study was funded by Takeda Pharmaceuticals Korea Co.


  • Conception or design: S.S.K., I.J.K.

  • Acquisition, analysis, or interpretation of data: J.M.K., S.S.K., J.H.K., M.K.K., T.N.K., S.H.L., C.W.L., J.Y.P., E.S.K., K.J.L., Y.S.C., D.K.K., I.J.K.

  • Drafting the work or revising: J.M.K., S.S.K., I.J.K.

  • Final approval of the manuscript: J.M.K., S.S.K., J.H.K., M.K.K., T.N.K., S.H.L., C.W.L., J.Y.P., E.S.K., K.J.L., Y.S.C., D.K.K., I.J.K.


1. Kim SG, Kim NH, Ku BJ, Shon HS, Kim DM, Park TS, Kim YS, Kim IJ, Choi DS. Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): a prospective observational DIPP-FACTOR study in Korea. J Diabetes Investig 2017;8:346–353.
2. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018;41:S73–S85. 29222379.
3. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2018 executive summary. Endocr Pract 2018;24:91–120. 29368965.
4. Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH. Committee of Clinical Practice Guideline of Korean Diabetes Association. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes Metab J 2017;41:337–348. 29086531.
5. van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 2018;41:1543–1556. 30030256.
6. Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 2014;37:1338–1345. 24574345.
7. Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 2018;41:69–78. 29109299.
8. Ko SH, Kim DJ, Park JH, Park CY, Jung CH, Kwon HS, Park JY, Song KH, Han K, Lee KU, Ko KS. Force Team for Diabetes Fact Sheet of the Korean Diabetes Association. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013: nationwide population-based cohort study. Medicine (Baltimore) 2016;95e4018. 27399082.
9. Korean Diabetes Association. Diabetes fact sheet in Korea 2018. updated 2018 May 14. Available from: http://www.diabetes.or.kr/pro/news/admin.php?category=A&code=admin&number=1546&mode=view.
10. Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468–475. 27659408.
11. Suk JH, Lee CW, Son SP, Kim MC, Ahn JH, Lee KJ, Park JY, Shin SH, Kwon MJ, Kim SS, Kim BH, Lee SH, Park JH, Kim IJ. Relationship between Cardiovascular Disease and Brachial-Ankle Pulse Wave Velocity (baPWV) in Patients with Type 2 Diabetes (REBOUND) Study Group. Current status of prescription in type 2 diabetic patients from general hospitals in Busan. Diabetes Metab J 2014;38:230–239. 25003077.
12. Yabe D, Seino Y. Type 2 diabetes via β-cell dysfunction in east Asian people. Lancet Diabetes Endocrinol 2016;4:2–3. 26577717.
13. Ha KH, Park CY, Jeong IK, Kim HJ, Kim SY, Kim WJ, Yoon JS, Kim IJ, Kim DJ, Kim S. Clinical characteristics of people with newly diagnosed type 2 diabetes between 2015 and 2016: difference by age and body mass index. Diabetes Metab J 2018;42:137–146. 29676543.
14. Kim JD, Lee WY. Insulin secretory capacity and insulin resistance in Korean type 2 diabetes mellitus patients. Endocrinol Metab (Seoul) 2016;31:354–360. 27546870.
15. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G. Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group. Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017;5:887–897. 28917544.
16. DeFronzo RA. Pathogenesis of type 2 diabetes; metabolic and molecular implication for identifying diabetes genes. Diabetes Rev 1997;5:177–269.
17. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787–835. 15308380.
18. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059–4067. 8923861.
19. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–549. 7623902.
20. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89–131.
21. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217–224. 12173692.
22. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463–478. 14764748.
23. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–1118. 15356308.
24. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471. 17517853.
25. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–1326. 23992601.
26. Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352i610. 26888822.
27. Kawalec P, Mikrut A, Lopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30:269–283. 24829965.
28. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710–719. 11315836.
29. Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH, Hennessy S. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2018;27:9–18. 29108130.
30. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:1615–1622. 22419732.
31. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871–E883. 17106061.
32. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD. ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013;62:3920–3926. 23863810.
33. Kintscher U, Law RE. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005;288:E287–E291. 15637349.
34. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016;165:305–315. 27322798.
35. Filipova E, Uzunova K, Kalinov K, Vekov T. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr 2017;990. 29163673.
36. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378–396. 11952022.
37. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861–866. 16007095.
38. Seki G, Endo Y, Suzuki M, Yamada H, Horita S, Fujita T. Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion. World J Nephrol 2012;1:146–150. 24175252.
39. Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004;27:1577–1583. 15220231.
40. Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN. IRIS Trial Investigators. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab 2017;102:914–922. 27935736.

Article information Continued

Funded by : Takeda Pharmaceuticals Korea Co.

Fig. 1

Study flowchart.

Fig. 2

Changes in the measured variables at 12 weeks and 26 weeks. Mean±standard error values at baseline, 12 weeks, and 26 weeks were calculated for (A) glycosylated hemoglobin (HbA1c), (B) homeostatic model assessment of insulin resistance (HOMA-IR), (C) high density lipoprotein cholesterol (HDL-C), and (D) triglycerides during 26-week treatments using glimepiride (closed triangles) or pioglitazone (closed quadrangles) for patients with type 2 diabetes mellitus who were concurrently receiving combination therapy using alogliptin and metformin. aP<0.05.

Table 1

Baseline demographic and clinical characteristics (ITT population)

Characteristic Pioglitazone (n=69) Glimepiride (n=66) P value
Age, yr 60.7±9.1 58.5±10.4 0.190
Male sex 34 (49.3) 30 (45.5) 0.657
Body weight, kg 64.0±10.0 65.8±10.3 0.295
BMI, kg/m2 24.4±3.2 24.9±2.8 0.327
Disease duration, yr 10.6±8.2 9.7±6.7 0.478
HbA1c, % 8.25±0.58 8.16±0.61 0.386
Fasting plasma glucose, mg/dL 171.6±30.0 170.8±30.9 0.880
SBP, mm Hg 124±13 125±13 0.646
DBP, mm Hg 72±10 74±10 0.294
Triglyceride, mg/dL 68 (87–155) 80 (96–176) 0.237
Total cholesterol, mg/dL 156±33 151±33 0.310
LDL-C, mg/dL 90±32 87±27 0.549
HDL-C, mg/dL 51±14 47±10 0.136
Hypertension 36 (52.2) 38 (37.6) 0.528
Dyslipidemia 40 (58.0) 41 (62.1) 0.623
Diabetic retinopathy 12 (17.4) 5 (7.6) 0.086
Diabetic neuropathy 19 (27.5) 16 (24.2) 0.662

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

ITT, intention-to-treat; BMI, body mass index; HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.

Table 2

Primary and secondary outcomes, according to treatment group at 26 weeks

Variable Pioglitazone Glimepiride Inter-group difference, P value
Primary outcome
 HbA1c (%) in ITT population
  Number 69 66
  Baseline 8.25±0.58 8.16±0.61 0.386
  Week 26 7.44±1.13 7.11±0.76
  Change from baseline −0.81±1.10 −1.05±0.87 0.165
  P value <0.001 <0.001
 HbA1c (%) in PP population
  Number 58 58
  Baseline 8.21±0.56 8.20±0.63 0.938
  Week 26 7.16±0.82 7.07±0.76
  Change from baseline −1.04±0.94 −1.12±0.87 0.630
  P value <0.001 <0.001
Secondary outcomes in PP population
 Total cholesterol, mg/dL
  Baseline 153.34±32.51 151.40±33.66
  Week 26 160.31±35.65 152.33±34.45
  Change from baseline 6.97±27.08 0.92±19.91 0.174
  P value 0.055 0.725
 Triglyceride, mg/dL
  Baseline 132.84±72.15 146.17±71.58
  Week 26 113.02±51.47 130.72±67.03
  Change from baseline −19.83±69.69 −15.45±56.76 0.711
  P value 0.034 0.043
 LDL-C, mg/dL
  Baseline 88.26±32.51 87.62±27.62
  Week 26 90.14±34.56 88.01±29.93
  Change from baseline 1.88±27.02 0.39±17.99 0.727
  P value 0.598 0.870
 HDL-C, mg/dL
  Baseline 49.19±14.20 47.22±9.91
  Week 26 54.76±18.18 48.16±11.29
  Change from baseline 5.57±9.58 0.94±8.47 0.007
  P value <0.001 0.403
  Baseline 4.10±3.03 3.98±3.01
  Week 26 2.58±1.56 3.43±2.69
  Change from baseline −1.53±2.74 −0.54±2.72 0.054
  P value <0.001 0.133
  Baseline 32.57±23.24 40.59±59.45
  Week 26 38.72±25.18 45.81±26.71
  Change from baseline 6.15±24.15 5.21±59.75 0.912
  P value 0.057 0.509

Values are presented as mean±standard deviation. P<0.05 was considered significant.

HbA1c, glycosylated hemoglobin; ITT, intention-to-treat; PP, per-protocol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment as an index of insulin resistance; HOMA-β, homeostatic model assessment β-cell function.

Table 3

Adverse events summary

Variable Pioglitazone (n=69) Glimepiride (n=66) P value
Adverse eventa 64 (92.8) 58 (87.9) 0.504
 Hypoglycemia 3 (4.4) 16 (24.2) 0.002
 Upper respiratory infection 10 (14.5) 6 (9.1) 0.481
 Dizziness 5 (7.3) 5 (7.6) 1.000
 Headache 3 (4.4) 2 (3.0) 1.000
 Weight gain 4 (5.8) 0 0.120
 Dyspepsia 0 4 (6.1) 0.055
 Acute diarrhea 2 (2.9) 1 (1.5) 1.000
 Itching 3 (4.4) 0 0.245
 Edema 3 (4.4) 0 0.245
 Abdominal pain 2 (2.9) 0 0.497
 Ache 2 (2.9) 0 0.497
 Myalgia 2 (2.9) 0 0.497
 Palpitation 0 2 (3.0) 0.237
Serious adverse event 3 (4.4) 0 0.245
 Fractureb 2 (2.9) 0 1.000
 Acute pyelonephritis 1 (1.5) 0 1.000
Adverse drug reaction 8 (11.6) 23 (34.9) 0.003
 Hypoglycemia 1 (1.5) 14 (21.2) 0.001
 Dizziness 1 (1.5) 3 (4.6) 0.358
 Weight gain 2 (2.9) 0 0.497
 Edema 2 (2.9) 0 0.497

Values are presented as number (%).

aOccurring in frequencies of ≥2% in either treatment group, bFractures of cuneiform bone of foot and intertrochanteric section of femur after falling.